Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumor angiogenesis.

M Detmar1

  • 1Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Charlestown 02129, USA. michael.detmar@cbrc2.mgh.harvard.edu

The Journal of Investigative Dermatology. Symposium Proceedings
|January 9, 2001
PubMed
Summary

Tumors require new blood vessel growth (angiogenesis) to expand and spread. Blocking vascular endothelial growth factor (VEGF) or using inhibitors like thrombospondin (TSP) can suppress tumor growth by inhibiting angiogenesis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interaction of tumor cells and lymphatic vessels in cancer progression.

Oncogene·2011
Same author

Isolation and culture of microvascular endothelial cells.

Methods in molecular medicine·2011
Same author

Quantitative lymphatic vessel trait analysis suggests Vcam1 as candidate modifier gene of inflammatory bowel disease.

Genes and immunity·2010
Same author

Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1.

The British journal of dermatology·2005
Same author

The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses.

The Journal of investigative dermatology·2001
Same author

Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma.

The American journal of pathology·2001

Area of Science:

  • Oncology
  • Vascular Biology
  • Molecular Biology

Background:

  • Tumor growth and metastasis depend on angiogenesis, the formation of new blood vessels.
  • Angiogenesis is regulated by a balance between angiogenic factors and inhibitors; tumors disrupt this balance.
  • Vascular endothelial growth factor (VEGF) is a key driver of tumor angiogenesis, promoting growth and invasion.

Purpose of the Study:

  • To review the role of VEGF in tumor angiogenesis.
  • To discuss the function of endogenous angiogenesis inhibitors, such as thrombospondin (TSP).
  • To highlight the therapeutic potential of targeting angiogenesis in cancer treatment.

Main Methods:

  • Review of existing scientific literature on tumor angiogenesis.
  • Analysis of the roles of VEGF family members and their receptors.
  • Examination of the inhibitory mechanisms of TSP-1 and TSP-2.

Main Results:

  • VEGF is a major factor promoting tumor growth, invasion, and metastasis.
  • Inhibition of VEGF function effectively suppresses tumor growth in vivo.
  • VEGF-C is implicated in lymphangiogenesis and Kaposi's sarcoma growth.
  • Thrombospondin-1 (TSP-1) and TSP-2 inhibit tumor growth by suppressing angiogenesis.

Conclusions:

  • Targeting VEGF offers a promising strategy for cancer therapy.
  • Endogenous inhibitors like TSP-1 and TSP-2 demonstrate potent anti-tumorigenic effects.
  • Understanding the balance of angiogenic factors and inhibitors is crucial for developing effective cancer treatments.

Related Experiment Videos